Skip to main content
. Author manuscript; available in PMC: 2010 Apr 1.
Published in final edited form as: Future Oncol. 2009 Jun;5(5):591–600. doi: 10.2217/fon.09.35

Table 3.

Bevacizumab in epithelial ovarian carcinoma (Phase II).

Variable Cannistra
(n = 44) (%)
Garcia*
(n = 70) (%)
Burger
(n = 62) (%)
Previous regimens
1 100 34
2 52
3 48
Response rate
CR 0 0 3
PR 16 24 18
GI perforations 11 6 0
Arterial thrombosis 7 4 0
Bevacizumab-related deaths 7 4 0
Ref. [8] [9] [7]
*

Combined with oral cyclophosphamide.

CR: Complete response; GI: Gastrointestinal; PR: Partial response.